Heart & blood Natriuretic peptide
Nesiritide
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Nesiritide (sold as Natrecor) is a laboratory-made copy of B-type natriuretic peptide, a hormone the heart releases when it is under strain, developed as an intravenous treatment for acute heart failure. It relaxes blood vessels and lowers heart-filling pressures, but a large trial later found it did not reduce death or rehospitalization. As of 2026 it has been FDA-approved in the U.S. since 2001, though it has largely been withdrawn from the market.
At a glance
- What it is
- Recombinant human B-type natriuretic peptide (BNP), a vasodilator
- Approved for
- Acute decompensated heart failure with shortness of breath at rest or minimal activity
- Key fact
- In the large ASCEND-HF trial it did not improve survival or rehospitalization and had only a small effect on symptoms
- Route
- Intravenous
- Evidence strength
- FDA-approved (discontinued)
Summary
Nesiritide is a lab-made copy of the heart hormone BNP, approved for acute heart failure. See how it works, what trials found, and its side effects.
What is nesiritide?
Nesiritide, sold under the brand Natrecor, is a recombinant form of human B-type natriuretic peptide (BNP), a hormone normally released by the heart's ventricles when they are stretched by excess pressure or volume. The drug was designed to amplify that natural signal in acute heart failure, promoting vessel relaxation and fluid removal. It was approved in the United States in 2001 and has since been largely withdrawn from the market for commercial reasons.
How does nesiritide work?
Nesiritide reproduces the 32-amino-acid sequence of human BNP and binds the natriuretic peptide receptor-A, raising the second messenger cyclic GMP in blood-vessel walls. This relaxes both arteries and veins, lowering the pressure the heart has to pump against and the pressure filling it (reflected as a lower pulmonary capillary wedge pressure). It also promotes sodium and water excretion by the kidney and dampens the renin-angiotensin-aldosterone system.
Those effects improve the hemodynamics of acute heart failure, but the two key trials reached different results:
| Trial | Findings |
|---|---|
| VMAC, the earlier trial | Nesiritide lowered filling pressure more than nitroglycerin or placebo and improved breathing at 3 hours |
| ASCEND-HF, the larger later trial | Only a small, non-significant effect on dyspnea and no benefit on 30-day death or rehospitalization, while increasing episodes of low blood pressure |
That gap between short-term hemodynamics and hard outcomes is the central story of the drug.
Is it FDA-approved?
Editor’s note
Status: Yes. Nesiritide was approved by the FDA in 2001 for acute decompensated heart failure in patients with shortness of breath at rest or with minimal activity. After the neutral ASCEND-HF results and shifting practice, the product was largely withdrawn from the U.S. market, so its approval is now mainly of historical interest.
Category: FDA-approved · Primary body area: Heart & blood
Yes. Nesiritide was approved by the FDA in 2001 for acute decompensated heart failure in patients with shortness of breath at rest or with minimal activity. After the neutral ASCEND-HF results and shifting practice, the product was largely withdrawn from the U.S. market, so its approval is now mainly of historical interest.
What is nesiritide prescribed for?
Nesiritide was prescribed for intravenous treatment of acute decompensated heart failure to relieve shortness of breath, given in a monitored hospital setting. In current practice it is rarely used, both because of the ASCEND-HF findings and because the product has been largely withdrawn.
What are the side effects?
Common side effects include:
- Low blood pressure, which can be symptomatic or prolonged
- Headache
- Nausea
More serious considerations include:
- Significant hypotension, the main safety concern
- Slowed heart rate
- Earlier concerns about worsening kidney function, which were not confirmed in ASCEND-HF
Sources: FDA prescribing information for Natrecor; the VMAC trial (2002) and O'Connor et al. (2011), the ASCEND-HF trial. PubMed-indexed studies are cited by DOI where used. This article is for educational purposes only and is not medical advice.
Registered human trials
2 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
Compare every peptide’s status in the peptide regulatory status database
More for Heart & blood
View all heart & blood peptides →- FDA-approved Heart & blood
Angiotensin-Ii
Angiotensin II is a natural peptide hormone and the main active signal of the renin-angiotensin system, which the body uses to raise blood pressure by tightening blood vessels. A synthetic version is FDA-approved as Giapreza, an intravenous drug given in intensive care to raise dangerously low blood pressure in adults with septic or other distributive shock. In its pivotal ATHOS-3 trial it raised blood pressure in about 70% of patients compared with 23% on placebo, though it also carries a risk of blood clots.
- In clinical trials Heart & blood
Balixafortide
Balixafortide is an investigational peptide that blocks the CXCR4 receptor, studied by Polyphor in combination with chemotherapy for metastatic breast cancer. An early single-arm trial suggested activity, but the pivotal Phase 3 trial did not show a benefit over chemotherapy alone, and development has effectively stopped. As of 2026 it is not approved.
- FDA-approved Heart & blood
Bivalirudin
Bivalirudin is a synthetic 20-amino acid peptide anticoagulant, derived in design from the leech protein hirudin, that directly and reversibly blocks thrombin, the central enzyme in blood clotting. Sold as Angiomax, it is given intravenously during coronary procedures such as angioplasty and stenting to prevent clots, including in people who cannot receive heparin. In a large trial of heart-attack patients, using it instead of heparin plus a second blood thinner reduced major bleeding and lowered 30-day death rates.
- FDA-approved Heart & blood
Desirudin
Desirudin (formerly sold as Iprivask) is a recombinant form of hirudin, the natural anticoagulant from the medicinal leech, that was used to prevent blood clots after hip replacement surgery. It directly and specifically blocks thrombin, the central enzyme of the clotting cascade. It was FDA-approved in the U.S. in 2003, but Iprivask has since been discontinued and no desirudin product is currently sold in the U.S.
- FDA-approved Heart & blood
Desmopressin
Desmopressin (desmopressin acetate; brands include DDAVP and Nocdurna) is a synthetic version of the antidiuretic hormone vasopressin, engineered to concentrate urine without raising blood pressure. It treats central diabetes insipidus, bedwetting, nighttime urination, and certain bleeding disorders. It has been FDA-approved in the U.S. since 1978 and comes as tablets, a sublingual form, nasal spray, and injection.
- FDA-approved Heart & blood
Echinocandins
The echinocandins (caspofungin, micafungin, and anidulafungin; sold as Cancidas, Mycamine, and Eraxis) are antifungal lipopeptides that attack the fungal cell wall, a structure human cells lack. They are a preferred option for invasive Candida infections and are generally well tolerated. All three have been FDA-approved in the U.S. since the 2000s, a fourth (rezafungin, sold as Rezzayo) was approved in 2023, and all are given intravenously.